FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management

发布时间： 2023-11-10 阅读：152次

分享

The US Food and Drug Administration (FDA) announced on November 8, 2023 that Lilly's Zepbound injection was approved for long-term weight management of adults, which is applicable to obese or overweight adults (BMI index should be at least 27), and has at least one weight related condition (such as hypertension, type II diabetes or high cholesterol), which needs to be used in combination with diet to control calorie intake and increase physical activity. Tirzepatide is the active ingredient in Zepbound, which has been approved under the trade name of Mounjaro to help improve the blood sugar level of adults with type II diabetes.

Lilly stated in its announcement that it expects Zepbound to debut in the US market before the end of the year, priced at $1059.87 per month, which is 20% lower than the pricing of its competitor, Megglutide Injection. For patients with commercial insurance, the minimum monthly expenditure can be reduced to $25. As of closing, Lilly rose 3.2% on Wednesday, with a market value close to $590 billion.